Skip to main content
Camlin Fine Sciences Ltd logo

Camlin Fine Sciences Ltd — Investor Relations & Filings

Ticker · CAMLINFINE ISIN · INE052I01032 LEI · 3358005CR8R9MY6DLY36 BSE.NS Manufacturing
Filings indexed 1,525 across all filing types
Latest filing 2019-06-01 Regulatory Filings
Country IN India
Listing BSE.NS CAMLINFINE

About Camlin Fine Sciences Ltd

https://www.camlinfs.com

Camlin Fine Sciences Ltd is a global provider of specialty chemicals, specializing in shelf-life extension solutions and aroma ingredients. The company is a leading manufacturer of traditional antioxidants, including Tertiary Butylhydroquinone (TBHQ) and Butylated Hydroxyanisole (BHA), which are utilized to maintain the stability and quality of food, feed, and industrial applications. Its product portfolio also features aroma chemicals such as vanillin and ethyl vanillin, supported by a vertically integrated manufacturing process. Camlin Fine Sciences serves a broad range of sectors, including human nutrition, animal health, pet food, pharmaceuticals, and fragrances. By utilizing advanced chemical synthesis and a global distribution network, the company delivers performance chemicals and customized blends designed to enhance product longevity and sensory characteristics.

Recent filings

Filing Released Lang Actions
The senior management team of the Company will be meeting various international investor and analyst from June 03, 2019 to June 06, 2019.
Regulatory Filings
2019-06-01 English
clarification on Audited Financial Results
Regulatory Filings
2019-05-31 English
Publish Audited Results
Regulatory Filings
2019-05-27 English
Financial Result Updates
Regulatory Filings
2019-05-27 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is an investor presentation dated May 25, 2019, related to the financial results for the quarter ended March 31, 2019 (Q4 FY19) and the full fiscal year FY19. It includes detailed financial data such as standalone and consolidated income statements, operational revenue, EBITDA, profit after tax, and segment business mix. The document also contains company overview, manufacturing facilities, R&D centers, and project updates. The text explicitly mentions it is an "investor presentation made for the conference call" and includes detailed financial and operational information typically presented to investors and analysts. It is not a full annual report (10-K), nor a regulatory filing or earnings release summary. The presence of detailed financial tables and business overview aligns with the definition of an Investor Presentation (IP).
2019-05-27 English
Results published in News Paper
Regulatory Filings
2019-05-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.